Computer models simulating liver responses to two thyroid medications show that propylthiouracil at standard doses is linked to a high predicted rate of liver stress, likely due to oxidative damage, while methimazole at its standard dose shows no such predicted risk, indicating the two drugs damage the liver through different biological processes.
Evidence from Studies
No evidence studies found yet.
What Would Prove This
Per GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this claim, ordered from strongest to weakest.
A systematic review of clinical trials and observational studies could establish whether the observed association between PTU and elevated ALT incidence is consistent across populations and whether MMI truly has lower hepatotoxicity risk in real-world settings.
A systematic review and meta-analysis of all published prospective cohort studies and randomized controlled trials comparing PTU (≥200 mg/day) and MMI (≥20 mg/day) in adults with hyperthyroidism, reporting ALT >2×ULN as a primary outcome, with adjustment for age, sex, dose duration, and comorbidities, including at least 10,000 patient-years of exposure data.
A randomized trial could determine whether switching from MMI to PTU increases the incidence of ALT elevation above baseline in hyperthyroid patients, directly testing the comparative hepatotoxicity risk.
A double-blind, multicenter RCT of 500 adults with newly diagnosed hyperthyroidism, randomized to receive either PTU (300 mg/day) or MMI (30 mg/day) for 24 weeks, with primary outcome being incidence of ALT >2×ULN, measured weekly, and secondary outcomes including bilirubin, INR, and symptom reporting, with exclusion of patients with pre-existing liver disease.
A prospective cohort study could quantify the real-world incidence of ALT elevation in patients prescribed PTU versus MMI over time, adjusting for confounders like age, dose, and duration.
A prospective cohort study following 10,000 adults prescribed PTU or MMI for hyperthyroidism in primary care, with monthly liver enzyme monitoring for 2 years, stratified by drug, dose, and genetic markers (e.g., HLA-B*35:01), controlling for alcohol use, obesity, and concomitant medications.
A case-control study could identify whether patients who develop ALT >2×ULN on antithyroid drugs are more likely to have been exposed to PTU than MMI, after matching for confounders.
A case-control study comparing 500 patients with drug-induced ALT >2×ULN (cases) to 1,500 matched controls without liver injury, all treated for hyperthyroidism, assessing prior exposure to PTU vs. MMI, dose, duration, and genetic variants, using hospital records and pharmacy data.
A cross-sectional analysis could describe the prevalence of elevated ALT among current users of PTU versus MMI at a single point in time.
A cross-sectional survey of 5,000 adults currently taking PTU or MMI for hyperthyroidism, measuring ALT levels at one visit and collecting data on drug type, dose, duration, and demographic factors, with exclusion of acute illness or other hepatotoxins.